ConductScience.org, home

Paper29252124

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A and 23 others. J Clin Oncol, 2018. Cited by 150 papers, by iCite.

Cite this record

ConductScience Library. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. Papers, record 29252124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29252124

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
PubMed
Journal
J Clin Oncol
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
150
iCite
Relative citation ratio, by iCite
4.3
iCite
Revised in PubMed
2025-05-30
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thomas AAnish
2Redon CEChristophe E
3Sciuto LLinda
4Padiernos EEmerson
5Ji JJiuping
6Lee MJMin-Jung
7Yuno AAkira
8Lee SSunmin
9Zhang YYiping
10Tran LLan
11Yutzy WWilliam
12Rajan AArun
13Guha UUdayan
14Chen HHaobin
15Hassan RRaffit
16Alewine CCChristine C
17Szabo EEva
18Bates SESusan E
19Kinders RJRobert J
20Steinberg SMSeth M

Source PubMed

See all 24 authorsDownload CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
IsoxazolesMajor topic
PyrazinesMajor topic
TopotecanMajor topic
Adult
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Treatment Outcome

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
ZIA BC011746Intramural NIH HHSUnited StatesZIABC011746PubMedNIH RePORTER
ZIA BC011793Intramural NIH HHSUnited StatesZIABC011793PubMedNIH RePORTER
ZICSC006743NIHNIH RePORTER
ZIEBC011653NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02487095Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersResultsYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in29369707Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells.https://conductscience.org/library/papers/29369707

Source PubMed

Download CSV of comments and corrections

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123451157Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.PLoS One2013https://conductscience.org/library/papers/23451157PubMed
222120667Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.Nat Struct Mol Biol2011https://conductscience.org/library/papers/22120667PubMed
319553641Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med2009https://conductscience.org/library/papers/19553641PubMed
411673449Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress.J Biol Chem2001https://conductscience.org/library/papers/11673449PubMed
528714480The impact of replication stress on replication dynamics and DNA damage in vertebrate cells.Nat Rev Genet2017https://conductscience.org/library/papers/28714480PubMed
622713662Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.Br J Cancer2012https://conductscience.org/library/papers/22713662PubMed
725269479ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Cancer Res2014https://conductscience.org/library/papers/25269479PubMed
821098704Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.Cancer Res2010https://conductscience.org/library/papers/21098704PubMed
924366029Causes and consequences of replication stress.Nat Cell Biol2014https://conductscience.org/library/papers/24366029PubMed
1027958275ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.Nat Commun2016https://conductscience.org/library/papers/27958275PubMed
1116990856Topoisomerase I inhibitors: camptothecins and beyond.Nat Rev Cancer2006https://conductscience.org/library/papers/16990856PubMed
1223222511Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.Cell Death Dis2012https://conductscience.org/library/papers/23222511PubMed
1328698210APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.Cancer Res2017https://conductscience.org/library/papers/28698210PubMed
1411121462Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest.J Natl Cancer Inst2000https://conductscience.org/library/papers/11121462PubMed
1528069806DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.J Immunol2017https://conductscience.org/library/papers/28069806PubMed
1627067599A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors.Mol Cell2016https://conductscience.org/library/papers/27067599PubMed
1725281304DNA replication stress: causes, resolution and disease.Exp Cell Res2014https://conductscience.org/library/papers/25281304PubMed
1826486755Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.Sci Rep2015https://conductscience.org/library/papers/26486755PubMed
1921552262A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.Nat Struct Mol Biol2011https://conductscience.org/library/papers/21552262PubMed
2021325706Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker.Aging (Albany NY)2011https://conductscience.org/library/papers/21325706PubMed

See all 32 referencesDownload CSV of references

Cited by112

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.

PMIDTitleJournalYearIn PapersSource
42816529Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.Br J Cancer2026https://conductscience.org/library/papers/42816529PubMed
42778539Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42778539PubMed
42410700Duocarmycin-Bearing Antibody-Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL-4 Xenograft Model.Cancer Med2026https://conductscience.org/library/papers/42410700PubMed
42232064Multi-omics dissection of R-loop dynamics in tumorigenesis: From transcription-replication conflict to therapeutic targets.Mol Ther Oncol2026https://conductscience.org/library/papers/42232064PubMed
42098732Synthetic lethality in cancer: mechanism exploration and therapeutic applications.Cell Commun Signal2026https://conductscience.org/library/papers/42098732PubMed
42092629Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads.J Mol Biol2026https://conductscience.org/library/papers/42092629PubMed
41896265Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models.Sci Rep2026https://conductscience.org/library/papers/41896265PubMed
41862351Replication origin flexibility: a tool to mitigate the hazards of excess replication.Trends Genet2026https://conductscience.org/library/papers/41862351PubMed
41823504A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).Cancer2026https://conductscience.org/library/papers/41823504PubMed
41575477Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules.Mol Divers2026https://conductscience.org/library/papers/41575477PubMed
41421295A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).ESMO Open2026https://conductscience.org/library/papers/41421295PubMed
41409249The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.Front Oncol2025https://conductscience.org/library/papers/41409249PubMed
41335461NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.Oncologist2025https://conductscience.org/library/papers/41335461PubMed
41190241Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors.NAR Cancer2025https://conductscience.org/library/papers/41190241PubMed
41160399Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).Cancer2025https://conductscience.org/library/papers/41160399PubMed
41105363Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications.Discov Oncol2025https://conductscience.org/library/papers/41105363PubMed
40859871Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies.J Cell Mol Med2025https://conductscience.org/library/papers/40859871PubMed
40848933Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future.J Mol Biol2026https://conductscience.org/library/papers/40848933PubMed
40523990Advancing therapeutics in small-cell lung cancer.Nat Cancer2025https://conductscience.org/library/papers/40523990PubMed
40437704Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study.Clin Pharmacol Drug Dev2025https://conductscience.org/library/papers/40437704PubMed

See all 112 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ATR545PubTator's text mininghttps://conductscience.org/library/genes/545NCBI Gene
TOP17150PubTator's text mininghttps://conductscience.org/library/genes/7150NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
BERZOSERTIBCHEMBL3989870Results1https://conductscience.org/library/drugs/CHEMBL3989870ChEMBL
TOPOTECANCHEMBL84Results1https://conductscience.org/library/drugs/CHEMBL84ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29252124

GET https://conductscience.org/api/papers/v1/29252124/authors?page=2